Which Low-Flow, Low-Gradient Patients Benefit from Valve Replacement?

A mean gradient ≥40 mmHg, an aortic valve area ≤1 cm², or a combination of both, during dobutamine stress echocardiography, correctly qualifies as severe aortic stenosis in about half of all patients. The other half consists in cases of pseudo-severe aortic stenosis.

¿Qué pacientes con bajo flujo y bajo gradiente se benefician del recambio valvular? In turn, a projected aortic valve area ≤1 cm² is a much better indicator than the aforementioned markers, correctly diagnosing 70% of all patients (a statistic that is still far from being perfect).

The American College of Cardiology/American Heart Association (ACC/AHA) guidelines consider that patients have true-severe stenosis when the mean gradient is ≥40 mmHg and an aortic valve area ≤1 cm² during dobutamine stress echocardiography. However, these criteria have not been previously validated, and nowadays we face the more pressing need to correctly classify patients according to their eligibility for percutaneous replacement.


Read also: TAVR in Low-Flow Low-Gradient Aortic Stenosis and Severe Impairment of Systolic Function.


Before transcatheter aortic valve replacement (TAVR), the correct diagnosis of low-flow, low-gradient patients was an academic issue, since most of them could not afford the risks of conventional surgery, anyways.

The aim of this study was to assess the value of these criteria to predict the presence of true-severe aortic stenosis in low-flow, low-gradient patients, and to assess their prognosis.

One hundred eighty-six patients with impaired ventricular function and low-flow, low-gradient ventricular severe aortic stenosis were prospectively enrolled and assessed through dobutamine stress echocardiography. Researchers conducted measurements of the mean gradient, the aortic valve area, and the projected aortic valve area, which is an estimate of the aortic valve area at a standardized normal flow rate. True severity of stenosis was independently corroborated by macroscopic evaluation at the time of valve replacement in 54 patients, by multislice computed tomography in 25 patients, and by both methods in 8 patients. According to these last parameters, only 50 of 87 (57%) patients had true-severe aortic stenosis.


Read also: Low Gradient Aortic Stenosis Won’t Improve with TAVR.


A mean gradient ≥40 mmHg, an aortic valve area ≤1 cm², or a combination of both, during dobutamine stress echocardiography, correctly classified 48%, 60%, and 47% of patients, respectively. On the other hand, projected aortic valve area ≤1 cm² correctly classified 70% of the population, thus being more precise than all other parameters (p < 0.007).

Among the population, 47% (88 patients) of all cases were managed conservatively. In this subset, 52 patients died during a follow-up of 2.8 ± 2.5 years.


Read also: ACC 2018 | Flu Vaccination Reduces Mortality in Heart Failure Hospitalizations.


After adjustment for age, sex, functional capacity, chronic kidney failure, etc., dobutamine stress mean gradient and aortic valve area were not predictors of mortality in this subset. In contrast, projected aortic valve area was a strong predictor of mortality for conservatively managed patients (hazard ratio [HR]: 3.65; p = 0.0003).

Conclusion

Parameters proposed in the guidelines to identify patients with low-flow low-gradient true-severe aortic stenosis have limited value to correctly identify actual aortic stenosis and to predict its outcomes.

Projected valve area better distinguishes true-severe aortic stenosis from pseudo-severe aortic stenosis and is strongly associated with mortality in patients under conservative management.

Original title: Dobutamine Stress Echocardiography for Management of Low-Flow, Low-Gradient Aortic Stenosis.

Reference: Mohamed-Salah Annabi et al. J Am Coll Cardiol 2018;71:475-85.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...

J-Valve for Chronic AR: 30-Day Outcomes of Transfemoral Valve J-Valve in Chronic Aortic Regurgitation

Chronic aortic regurgitation (AR) poses a significant challenge as far as transcatheter alternatives go due to the absence of calcification and a suitable anchoring...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...